Investigational drugs in clinical trials for macular degeneration

References

• Owsley C, McGwin GsJr., Clark ME, et al. Delayed rod-mediated dark adaptation is a functional biomarker for incident early age-related macular degeneration. Ophthalmology. 2016 Feb;123(2):344–351.
   PubMed Web of Science ®Google Scholar
• Nusinowitz S, Wang Y, Kim P, et al. Retinal structure in pre-clinical age-related macular degeneration. Curr Eye Res. 2018 Mar;43(3):376–382.
   PubMed Web of Science ®Google Scholar
• Pinelli R, Bertelli M, Scaffidi E, et al. Measurement of drusen and their correlation with visual symptoms in patients affected by age-related macular degeneration. Arch Ital Biol. 2020 Dec 1;158(3–4):82–104.
   PubMed Web of Science ®Google Scholar
• Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018 Mar;125(3):369–390.
   PubMed Web of Science ®Google Scholar
• Burguera-Gimenez N, Garcia-Lazaro S, Espana-Gregori E, et al. Multimodal evaluation of visual function in geographic atrophy versus normal eyes. Clin Ophthalmol. 2020;14:1533–1545.
   PubMed Web of Science ®Google Scholar
• Fu DJ, Faes L, Wagner SK, et al. Predicting incremental and future visual change in neovascular age-related macular degeneration using deep learning. Ophthalmol Retina. 2021 Nov;5(11):1074–1084.
   PubMedGoogle Scholar
• Schneider EW, Mruthyunjaya P, Talwar N, et al. Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade. Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):542–549.
   PubMed Web of Science ®Google Scholar
• Ban N, Lee TJ, Sene A, et al. Impaired monocyte cholesterol clearance initiates age-related retinal degeneration and vision loss. JCI Insight. 2018 Sep 6;3(17).
   Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001 Oct;119(10):1417–1436.
   PubMedGoogle Scholar
• Pyle CJ, Akhter S, Bao S, et al. Zinc modulates endotoxin-induced human macrophage inflammation through ZIP8 Induction and C/EBPbeta inhibition. PLoS One. 2017;12(1):e0169531.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kambhampati SP, Bhutto IA, et al. Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model. Exp Eye Res. 2021 Feb;203:108391.
   PubMed Web of Science ®Google Scholar
• Yu C, Roubeix C, Sennlaub F, et al. Microglia versus monocytes: distinct roles in degenerative diseases of the retina. Trends Neurosci. 2020 Jun;43(6):433–449.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wong WT. Innate immunity in age-related macular degeneration. Adv Exp Med Biol. 2021;1256:121–141.
   PubMed Web of Science ®Google Scholar
• Ban N, Lee TJ, Sene A, et al. Disrupted cholesterol metabolism promotes age-related photoreceptor neurodegeneration. J Lipid Res. 2018 Aug;59(8):1414–1423.
   PubMed Web of Science ®Google Scholar
• Yu Y, Reynolds R, Rosner B, et al. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest Ophthalmol Vis Sci. 2012 Mar;53(3):1548–1556.
   PubMed Web of Science ®Google Scholar
• Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000 May;14(7):835–846.
   PubMed Web of Science ®Google Scholar
• Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cell Mol Life Sci. 2021 May;78(10):4487–4505.
   PubMed Web of Science ®Google Scholar
• Wu J, Wu YQ, Ricklin D, et al. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009 Jul;10(7):728–733.
   PubMed Web of Science ®Google Scholar
• Clark SJ, Ridge LA, Herbert AP, et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol. 2013 Mar 1;190(5):2049–2057.
   PubMed Web of Science ®Google Scholar
• Fearon DT. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971–1975.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Fearon DT, Austen KF. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol. 1979 Jan;122(1):75–81.
   PubMed Web of Science ®Google Scholar
• Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry. 2013 Jun 11;52(23):3949–3962.
   PubMed Web of Science ®Google Scholar
• Hyvarinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood. 2016 Jun 2;127(22):2701–2710.
   PubMed Web of Science ®Google Scholar
• Parente R, Clark SJ, Inforzato A, et al. Complement factor H in host defense and immune evasion. Cell Mol Life Sci. 2017 May;74(9):1605–1624.
   PubMed Web of Science ®Google Scholar
• Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology. 2008 Jun;115(6):1019–1025.
   PubMed Web of Science ®Google Scholar
• Peter I, Huggins GS, Ordovas JM, et al. Evaluation of new and established age-related macular degeneration susceptibility genes in the Women’s Health Initiative Sight Exam (WHI-SE) study. Am J Ophthalmol. 2011 Dec;152(6):1005–1013 e1.
   PubMed Web of Science ®Google Scholar
• Seddon JM, Francis PJ, George S, et al. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007 Apr 25;297(16):1793–1800.
   PubMed Web of Science ®Google Scholar
• Seddon JM, George S, Rosner B, et al. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered. 2006;61(3):157–165.
   PubMed Web of Science ®Google Scholar
• Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009 May;50(5):2044–2053.
   PubMed Web of Science ®Google Scholar
• Yu J, Wiita P, Kawaguchi R, et al. Biochemical analysis of a common human polymorphism associated with age-related macular degeneration. Biochemistry. 2007 Jul 17;46(28):8451–8461.
   PubMed Web of Science ®Google Scholar
• Whitmore SS, Sohn EH, Chirco KR, et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res. 2015 Mar;45:1–29.
   PubMed Web of Science ®Google Scholar
• An E, Sen S, Park SK, et al. Identification of novel substrates for the serine protease HTRA1 in the human RPE secretome. Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3379–3386.
   PubMed Web of Science ®Google Scholar
• Chen CY, Melo E, Jakob P, et al. N-Terminomics identifies HtrA1 cleavage of thrombospondin-1 with generation of a proangiogenic fragment in the polarized retinal pigment epithelial cell model of age-related macular degeneration. Matrix Biol. 2018 Sep;70:84–101.
   PubMed Web of Science ®Google Scholar
• Munoz SS, Li H, Ruberu K, et al. The serine protease HtrA1 contributes to the formation of an extracellular 25-kDa apolipoprotein E fragment that stimulates neuritogenesis. J Biol Chem. 2018 Mar 16;293(11):4071–4084.
   PubMed Web of Science ®Google Scholar
• Haapasalo K, van Kessel K, Nissila E, et al. Complement factor H binds to human serum apolipoprotein e and mediates complement regulation on high density lipoprotein particles. J Biol Chem. 2015 Nov 27;290(48):28977–28987.
   PubMed Web of Science ®Google Scholar
• Terwel D, Steffensen KR, Verghese PB, et al. Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. J Neurosci. 2011 May 11;31(19):7049–7059.
   PubMed Web of Science ®Google Scholar
• Killingsworth MC, Sarks JP, Sarks SH. Macrophages related to Bruch’s membrane in age-related macular degeneration. Eye (Lond). 1990;4(4):613–621.
   PubMedGoogle Scholar
• Weismann D, Hartvigsen K, Lauer N, et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 2011 Oct 5;478(7367):76–81.
   PubMed Web of Science ®Google Scholar
• Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem. 2003 Oct 24;278(43):613–621.
   Web of Science ®Google Scholar
• Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14682–14687.
   PubMed Web of Science ®Google Scholar
• Salomon RG, Hong L, Hollyfield JG. Discovery of carboxyethylpyrroles (CEPs): critical insights into AMD, autism, cancer, and wound healing from basic research on the chemistry of oxidized phospholipids. Chem Res Toxicol. 2011 Nov 21;24(11):1803–1816.
   PubMed Web of Science ®Google Scholar
• Saeed AM, Duffort S, Ivanov D, et al., The oxidative stress product carboxyethylpyrrole potentiates TLR2/TLR1 inflammatory signaling in macrophages. PLoS One. 2014;9(9):e106421.
   PubMed Web of Science ®Google Scholar
• Kim YW, Yakubenko VP, West XZ, et al. Receptor-mediated mechanism controlling tissue levels of bioactive lipid oxidation products. Circ Res. 2015 Jul 31;117(4):321–332.
   PubMed Web of Science ®Google Scholar
• Cao X, Shen D, Patel MM, et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int. 2011 Sep;61(9):528–535.
   PubMed Web of Science ®Google Scholar
• Cruz-Guilloty F, Saeed AM, Echegaray JJ, et al. Infiltration of proinflammatory m1 macrophages into the outer retina precedes damage in a mouse model of age-related macular degeneration. Int J Inflam. 2013;2013:503725.
   PubMedGoogle Scholar
• Jiao H, Provis JM, Natoli R, et al. Ablation of C3 modulates macrophage reactivity in the outer retina during photo-oxidative damage. Mol Vis. 2020;26:679–690.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005 May 27;308(5726):1314–1318.
   PubMed Web of Science ®Google Scholar
• Rong R, Yang R, Li H, et al. The roles of mitochondrial dynamics and NLRP3 inflammasomes in the pathogenesis of retinal light damage. Ann N Y Acad Sci. 2021 Nov 6;1508(1):78–91.
   PubMed Web of Science ®Google Scholar
• Datta S, Cano M, Ebrahimi K, et al. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017 Sep;60:201–218.
   PubMed Web of Science ®Google Scholar
• Ma W, Coon S, Zhao L, et al. A2E accumulation influences retinal microglial activation and complement regulation. Neurobiol Aging. 2013 Mar;34(3):943–960.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhao L, Wong WT. Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration. Adv Exp Med Biol. 2012;723:37–42.
   PubMed Web of Science ®Google Scholar
• Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res. 2015 Sep 4;1619:1–11.
   PubMed Web of Science ®Google Scholar
• Klaus C, Hansen JN, Ginolhac A, et al. Reduced sialylation triggers homeostatic synapse and neuronal loss in middle-aged mice. Neurobiol Aging. 2020 Apr;88:91–107.
   PubMed Web of Science ®Google Scholar
• Klaus C, Liao H, Allendorf DH, et al. Sialylation acts as a checkpoint for innate immune responses in the central nervous system. Glia. 2021 Jul;69(7):1619–1636.
   PubMed Web of Science ®Google Scholar
• Liao H, Klaus C, Neumann H. Control of innate immunity by sialic acids in the nervous tissue. Int J Mol Sci. 2020 Jul 31;21(15):5494.
   Web of Science ®Google Scholar
• Jiao H, Rutar M, Fernando N, et al. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. Mol Neurodegener. 2018 Aug 20;13(1):45.
   PubMedGoogle Scholar
• Yang Y, Liu F, Tang M, et al. Macrophage polarization in experimental and clinical choroidal neovascularization. Sci Rep. 2016 Aug 4;6(1):30933.
   PubMedGoogle Scholar
• Allendorf DH, Puigdellivol M, Brown GC. Activated microglia desialylate their surface, stimulating complement receptor 3-mediated phagocytosis of neurons. Glia. 2020 May;68(5):989–998.
   PubMed Web of Science ®Google Scholar
• Krogh Nielsen M, Subhi Y, Molbech CR, et al. Systemic levels of interleukin-6 correlate with progression rate of geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):202–208.
   PubMed Web of Science ®Google Scholar
• Krogh Nielsen M, Subhi Y, Molbech CR, et al. Patients with a fast progression profile in geographic atrophy have increased CD200 expression on circulating monocytes. Clin Exp Ophthalmol. 2019 Jan;47(1):69–78.
   PubMed Web of Science ®Google Scholar
• Subhi Y, Krogh Nielsen M, Molbech CR, et al. Association of CD11b+ monocytes and anti-vascular endothelial growth factor injections in treatment of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. JAMA Ophthalmol. 2019 May 1;137(5):515–522.
   PubMed Web of Science ®Google Scholar
• Subhi Y, Krogh Nielsen M, Molbech CR, et al. Polypoidal choroidal vasculopathy associate with diminished regulatory T cells that are polarized into a T helper 2-like phenotype. Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2583–2590.
   PubMed Web of Science ®Google Scholar
• Subhi Y, Krogh Nielsen M, Molbech CR, et al. Plasma markers of chronic low-grade inflammation in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Acta Ophthalmol. 2019 Feb;97(1):99–106.
   PubMed Web of Science ®Google Scholar
• Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest. 2011 Mar;121(3):985–997.
   PubMed Web of Science ®Google Scholar
• Sindrilaru A, Scharffetter-Kochanek K. Disclosure of the culprits: macrophages-versatile regulators of wound healing. Adv Wound Care (New Rochelle). 2013 Sep;2(7):357–368.
   PubMedGoogle Scholar
• Koh TJ, Novak ML, Mirza RE. Assessing macrophage phenotype during tissue repair. Methods Mol Biol. 2013;1037:507–518.
   PubMedGoogle Scholar
• Novak ML, Koh TJ. Macrophage phenotypes during tissue repair. J Leukoc Biol. 2013 Jun;93(6):515–581.
   Web of Science ®Google Scholar
• Novak ML, Koh TJ. Phenotypic transitions of macrophages orchestrate tissue repair. Am J Pathol. 2013 Nov;183(5):1352–1363.
   PubMed Web of Science ®Google Scholar
• Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron. 2014 Jan 22;81(2):229–248.
   PubMed Web of Science ®Google Scholar
• Lech M, Anders HJ. Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim Biophys Acta. 2013 Jul;1832(7):989–997.
   PubMed Web of Science ®Google Scholar
• Ferrante CJ, Pinhal-Enfield G, Elson G, et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation. 2013 Aug;36(4):921–931.
   PubMed Web of Science ®Google Scholar
• Song J, Lee K, Park SW, et al. Lactic acid upregulates VEGF expression in macrophages and facilitates choroidal neovascularization. Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3747–3754.
   PubMed Web of Science ®Google Scholar
• Sakurai E, Anand A, Ambati BK, et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3578–3585.
   PubMed Web of Science ®Google Scholar
• Karlstetter M, Kopatz J, Aslanidis A, et al. Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina. EMBO Mol Med. 2017 Feb;9(2):154–166.
   PubMed Web of Science ®Google Scholar
• Laubli H, Varki A. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cell Mol Life Sci. 2020 Feb;77(4):593–605.
   PubMed Web of Science ®Google Scholar
• Langmann T, Fauser S. Polysialic Acid for Immunomodulation in an animal model for wet Age-Related Macular Degeneration (AMD). Klin Monbl Augenheilkd. 2017 May;234(5):657–661.
   PubMed Web of Science ®Google Scholar
• Healthcare G. The dominance of eylea is expected to persist in the foreseeable future pharmaceutical technology2021 [updated 2021 Dec 1]. Available from: https://www.pharmaceutical-technology.com/comment/eylea-bayer-regeneron/
   Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021 Jan;128(1):89–99.
   PubMed Web of Science ®Google Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020 Oct;127(10):1345–1359.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020 Jan;127(1):72–84.
   PubMed Web of Science ®Google Scholar
• Witkin AJ, Hahn P, Murray TG, et al. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. J Vitreoretin Dis. 2021 Jul;5(4):326–332.
   PubMedGoogle Scholar
• Tolentino MJ, Husain D, Theodosiadis P, et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000 Jan;118(1):78–84.
   PubMedGoogle Scholar
• Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996 Jan;114(1):66–71.
   PubMed Web of Science ®Google Scholar
• Therapeutics O. ONS-5010/LYTENAVA™ OVERVIEW. Available from: https://outlooktherapeutics.com/lytenava-overview/
   Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials, Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials, Research G, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016 Aug;123(8):1751–1761.
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials, Research G, Writing C, Martin DF, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2020 Apr;127(4):S135–S145.
   PubMed Web of Science ®Google Scholar
• Schmid MK, Bachmann LM, Fas L, et al. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015 Feb;99(2):141–146.
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018 Jun 1;136(6):666–677.
   PubMed Web of Science ®Google Scholar
• Barratt J, Weitz I. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. 2021;12:712572.
   PubMed Web of Science ®Google Scholar
• Celkova L, Doyle SL, Campbell M. NLRP3 inflammasome and pathobiology in AMD. J Clin Med. 2015 Jan 14;4(1):172–192.
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014 Mar;121(3):693–701.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2018 Oct;125(10):1556–1567.
   PubMed Web of Science ®Google Scholar
• Dobri N, Qin Q, Kong J, et al. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):85–95.
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013 Mar;33(3):498–507.
   PubMed Web of Science ®Google Scholar
• Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc. 2003 May;35(3):18S–24S.
   PubMedGoogle Scholar
• Gensler G, Clemons TE, Domalpally A, et al. Treatment of geographic atrophy with intravitreal sirolimus: the age-related eye disease study 2 ancillary study. Ophthalmol Retina. 2018 May;2(5):441–450.
   PubMedGoogle Scholar
• Costagliola C, Semeraro F, Cipollone U, et al. Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1031–1037.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019 Aug;126(8):1141–1154.
   PubMed Web of Science ®Google Scholar
• Sharma A, Parachuri N, Kumar N, et al. The port delivery system with ranibizumab-journey of mitigating vitreous hemorrhage. Eye (Lond). 2022 Mar;36(3):488-489.
   Web of Science ®Google Scholar
• Baker-Schena, L. Drug delivery for the posterior segment. EyeNet Magazine. 2019;23(5):38-44.
   Google Scholar
• Heier J, Campochiaro P, Ho A, et al. Key takeaways from the RGX-314 phase I/IIa clinical trial for wet AMD (Cohorts 1-5). San Francisco CA2019: American Academy of Ophthamology.
   Google Scholar
• Khanani AM. Retina society. 2021 Sept 29 https://ocutx.gcs-web.com/static-files/3c59d3b0-9995-4e63-a972-e233a7550b1b; Chicago, IL2021
   Google Scholar
• ABC Platform. Available from: https://kodiak.com/our-science/
   Google Scholar
• Chandrasekaran PR, Madanagopalan VG. KSI-301: antibody biopolymer conjugate in retinal disorders. Ther Adv Ophthalmol. 2021 Jan-Dec;13:25158414211027708.
   Web of Science ®Google Scholar
• A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD) [Internet]. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03345082.
   Google Scholar
• Baldwin M. Phase 2b clinical results of OPT-302 (VEGF-C/D ‘Trap’) combination treatment in nAMD. San Francisco CA. San Francisco: Ophthalmology Innovation Summit @ American Academy of Ophthalmlogy; 2019.
   Google Scholar
• Liu K, Song Y, Xu G, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 phoenix study. Am J Ophthalmol. 2019 Jan;197:156–167.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-1). 2020.
   Google Scholar
• Rahal FM. Safety and efficacy results of ONS-5010, as ophthalmic bevacizumab, phase 3 pivotal study of monthly intravitreal OS-5010 in subjects with wet AMD (NORSE TWO). Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference; New Orleans, LA2021.
   Google Scholar
• Chakravarthy U, Bailey C, Brown D, et al. Phase I trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina. 2017 Nov - Dec;1(6):474–485.
   PubMedGoogle Scholar
• A proof-of-concept study of Faricimab (RO6867461) in participants with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) ClinicalTrials.gov.2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02484690.
   Google Scholar
• Study to evaluate faricimab (RO6867461; RG7716) for extended durability in the treatment of neovascular age related macular degeneration (nAMD) ClinicalTrials.gov2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03038880.
   Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729–740.
   PubMed Web of Science ®Google Scholar
• Asclepix. AXT107. Available from: https://asclepix.com/technology/
   Google Scholar
• Safety and bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA) 2021 [updated 2021 Mar 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT04746963
   Google Scholar
• Ren X, Li J, Xu X, et al. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res. 2016 Apr;145:352–358.
   PubMed Web of Science ®Google Scholar
• Innovent announces the results of the phase ib clinical trial of IBI302, a first-in-class anti-vegf and anti-complement bi-specific fusion protein for neovascular age-related macular degeneration at 2021 american academy of ophthalmology [Internet]. CISION PR Newswire; Nov 14, 2021
   Google Scholar
• Boyer DS New developments in drug therapy for retinal disorders. Hawaiian Eye & Retina Annual Meeting; Jan 21,2019; Kona, HI2019.
   Google Scholar
• Graybug vision reports full-data analysis from 12-month treatment phase of ALTISSIMO phase 2b trial in wet AMD [Internet]; May 12, 2021. Available from: https://investors.graybug.vision/news-releases/news-release-details/graybug-vision-reports-full-data-analysis-12-month-treatment
   Google Scholar
• Chaney P. PAN-90806: once-daily topical anti-VEGF eye drop for wet AMD and other neovascular eye disease. Ophthalmology Innovation Summit at the American Academy of Ophthalmology annual meeting (OIS@AAO); Oct 10, 2019; San Francisco, CA2019.
   Google Scholar
• BIOMEDICAL C. CLEARSIDE biomedical corporate overview. Available from: https://clearsidebio.com/about/
   Google Scholar
• BIOMEDICAL C. OASIS phase 1/2a clinical trial safety results 2021 [updated 2021 Dec 21]. Available from: https://ir.clearsidebio.com/static-files/73cbcd76-02e8-472b-88dd-c8985318c66e
   Google Scholar
• Kaiser E New sustained-release anti-VEGF formulation EYP-1901 proves safe, effective in phase 1 trials. Ophthalmology Times. 2021.
   Google Scholar
• Therapeutix O OTX-TKI sustained-release product candidate for retinal diseases. Available from: https://www.ocutx.com/research/otx-tki/
   Google Scholar
• Wong JG, Chang A, Guymer RH, et al. Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of Neovascular Age-Related Macular Degeneration (nAMD). ARVO Annual Meeting; May 2021; Virtual2021;62(8):218..
   Google Scholar
• John AW, Christine M, Gonzales RsMD, et al., A phase 1, open-label, dose-escalation trial to investigate safety and tolerability of single intravitreous injections of ICON-1 targeting tissue factor in wet AMD. OSLI Retina. 2018. 49(5):336-345.
   Google Scholar
• BG GCR. A phase 2 study (EMERGE) evaluating repeated intravitreal administration of ICON-1 in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2017;58:3766.
   Web of Science ®Google Scholar
• Open-label study of intravitreal ICON-1 in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) Clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03452527
   Google Scholar
• E J. AKST4290: an oral small molecule CCR3 antagonist. Ophthamology Innovation Summit; July 25,2019; Chicago, IL2019.
   Google Scholar
• Mugisho OO, Rupenthal ID, Paquet-Durand F, et al. Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease. Expert Opin Ther Targets. 2019 Oct;23(10):855–863.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing new-onset exudation in the randomized phase 2 filly trial of complement inhibitor pegcetacoplan for geographic atrophy. Ophthalmology. 2021 Sep;128(9):1325–1336.
   PubMed Web of Science ®Google Scholar
• Steinle NC, Pearce I, Mones J, et al. Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan. Am J Ophthalmol. 2021 Jul;227:116–124.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021 Apr;128(4):576–586.
   PubMed Web of Science ®Google Scholar
• McCaleb GJJJSSFRSGESM. Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD. Investigative Ophthalmology And Visual Science. 2020;61(7):4305.
   Web of Science ®Google Scholar
• Kiss S. Interim results from a first-in- human phase I/II gene therapy study (FOCUS) of GT005, an investigational AAV2 Vector encoding Complement Factor I (CFI), in patients with Geographic Atrophy (GA). Retina Society; Chicago Il; 2021.
   Google Scholar
• Therapeutics G. Gemini therapeutics announces initial data from its ongoing phase 2a study of GEM103 in patients with geographic atrophy secondary to dry age-related macular degeneration [cited 2021 Jun 22]. Available from: https://investors.geminitherapeutics.com/news/news-details/2021/Gemini-Therapeutics-Announces-Initial-Data-From-Its-Ongoing-Phase-2a-Study-of-GEM103-in-Patients-With-Geographic-Atrophy-Secondary-to-Dry-Age-Related-Macular-Degeneration/default.aspx
   Google Scholar
• Khanani AM, Hershberger VS, Pieramici DJ, et al. Phase 1 study of the anti-htra1 antibody-binding fragment FHTR2163 in geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol. 2021 Dec;232:49–57.
   PubMed Web of Science ®Google Scholar
• Obi C, Smith AT, Hughes GJ, et al. Targeting mitochondrial dysfunction with elamipretide. Heart Fail Rev. 2022 Jan 17.
   PubMed Web of Science ®Google Scholar
• Allingham MJsMP, Cousins SW. Elamipretide, a mitochondrial-targeted drug, for the treatment of vision loss in dry AMD with high risk drusen: results of the phase 1 ReCLAIM study. Invest Ophthalmol Vis Sci. 2019;60:361.
   Web of Science ®Google Scholar
• Ma L, Kaufman Y, Zhang J, et al. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011 Mar 11;286(10):7966–7974.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Gregori NZ, Ciulla TA, et al. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. 2018 Apr;19(5):471–481.
   PubMed Web of Science ®Google Scholar
• Cell L. OpRegen for dry AMD. Available from: https://lineagecell.com/products-pipeline/opregen/
   Google Scholar
• Ho AC, Chang TS, Samuel M, et al. Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol. 2017 Jul;179:67–80.
   PubMed Web of Science ®Google Scholar
• Heier JS, Ho AC, Samuel MA, et al. Safety and efficacy of subretinally administered palucorcel for geographic atrophy of age-related macular degeneration: phase 2b study. Ophthalmol Retina. 2020 Apr;4(4):384–393.
   PubMedGoogle Scholar
• Kashani AH, Lebkowski JS, Rahhal FM, et al. One-year follow-up in a phase 1/2a clinical trial of an allogeneic RPE cell bioengineered implant for advanced dry age-related macular degeneration. Transl Vis Sci Technol. 2021 Aug 12;10(10):13.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007 Dec;144(6):850–857.
   PubMed Web of Science ®Google Scholar
• Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):122–129.
   PubMed Web of Science ®Google Scholar
• Bonilha VL, Bell BA, Hu J, et al. Geographic atrophy: confocal scanning laser ophthalmoscopy, histology, and inflammation in the region of expanding lesions. Invest Ophthalmol Vis Sci. 2020 Jul 1;61(8):15.
   PubMed Web of Science ®Google Scholar
• Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223(2):69–76.
   PubMed Web of Science ®Google Scholar
• Liao H, Winkler J, Wissfeld J, et al. Low molecular weight polysialic acid prevents lipopolysaccharide-induced inflammatory dopaminergic neurodegeneration in humanized SIGLEC11 transgenic mice. Glia. 2021 Dec;69(12):2845–2862.
   PubMed Web of Science ®Google Scholar
• Lunemann JD, von Gunten S, Neumann H. Targeting sialylation to treat central nervous system diseases. Trends Pharmacol Sci. 2021 Dec;42(12):998–1008.
   PubMed Web of Science ®Google Scholar
• Kahler CM, Martin LE, Shih GC, et al. The (alpha2–>8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun. 1998 Dec;66(12):5939–5947.
   PubMed Web of Science ®Google Scholar